Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
Randomized double-blind placebo-controlled crossover study design
• Clinical diagnosis of heart failure
• No plan for titration/change of heart failure medical or device therapies during the study period.
• Absence of non-elective hospitalizations in the previous 2 months.
• At optimal volume status by symptoms, exam, and dry weight.
• Serum potassium ≤ 5.0 mmol/L
• Serum sodium ≥ 130 milliequivalents/ liter (mEq/L)
• Hemoglobin ≥8 g/dL
• Age \>18 years
• Objective evidence of diuretic resistance to a 10mg bumetanide challenge (screening visit may occur under this protocol or HIC2000032328 or HIC2000034315) defined as:
‣ FENa \<10% and total sodium output \<150mmol
⁃ And at least one of the following criteria:
• Chronic home furosemide dose greater than or equal to 80mg furosemide equivalents
∙ eGFR \< 60ml/min
∙ Serum chloride \<100mmol/L
∙ FENa \<5% and total sodium output \<75mmol on the 2 hour